Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).
Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse ev...
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more impo...
Lorraine Cheryl Pelosof, MD, PhD, of UT Southwestern Medical Center, discusses her study findings, which demonstrate an increasing proportion of never-smokers among patients with n...
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerat...
